Tristel PLC
TSNLF
Other OTC5.53
USD
- -
- -
ISIN
GB00B07RVT99
Return %
Stock
S&P500
1Y
4.54
26.53
3Y
380.87
76.60
5Y
380.87
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Matthew Giovanni Sassone
- Full Time Employees
- 233
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Lynx Business Park Snailwell United Kingdom
- IPO Date
- Jul 17, 2014
- Website
- tristel.com
- Similar Companies
- Business
- Tristel plc is a United Kingdom-based infection prevention company specializing in the development, manufacture, and sale of products that utilize proprietary chlorine dioxide chemistry for the decontamination of medical devices and sporicidal disinfection of hospital environmental surfaces. The company operates through three primary segments: hospital medical device decontamination, hospital environmental surface disinfection, and other related products. Its product portfolio includes a range of medical device decontamination solutions such as wipes system, ULT, OPH, Stella system, Fuse for Stella, Rinse Assure, Clean, EVE, Medistel, EVA system, Daisygrip, Fuse for Surfaces, Dosing System, Airstel, Enzystel, DOK, and pre-clean wipes, as well as surface disinfection products including FUSE, JET, JET LUX, JET PRO, TANK 10 CLO2, TANK 5 CLO2, and TILT 5 CLO2. The company additionally offers 3T, a cloud-based platform providing digital compliance and traceability for decontamination events. Tristel's products serve various clinical settings including airway management, cardiology, ENT, endoscopy, ophthalmology, phlebotomy, ultrasound, and women's health, targeting hospitals and healthcare facilities globally. Founded in 1993 and headquartered in Snailwell, Cambridgeshire, United Kingdom, Tristel markets its products primarily across the UK, Australia, Germany, Western Europe, and other international markets. In the last 1-2 years, the company has seen significant strategic developments, including the FDA clearance of its Tristel OPH high-level disinfectant product for ultrasound probes, expanding its point-of-care disinfection product offerings in the U.S. market. Tristel has also formed a commercial partnership with Parker Laboratories Inc. to manufacture and distribute chlorine dioxide foam disinfectants. The company continues to advance its digital compliance solutions with its cloud-based 3T platform, enhancing audit and reporting capabilities while expanding operational scalability. Financially, Tristel has backed its growth prospects with ongoing investments in innovation and operational efficiencies, including supply chain enhancements that have reduced unit costs and improved profitability. Tristel plc's industry focus lies in healthcare, particularly within medical instruments and infection control, addressing critical healthcare needs through scientifically validated, chlorine dioxide-based disinfection technologies. The company operates with a global ambition to lead in sporicidal disinfection and point-of-care medical device decontamination, supporting healthcare providers worldwide in infection prevention and control initiatives. The company employs approximately 250 people and continues to leverage its proprietary technology and R&D expertise to sustain product reliability and regulatory compliance internationally. Overall, Tristel plc stands out as a specialized infection prevention company with a comprehensive product suite based on chlorine dioxide chemistry, recent FDA regulatory wins, expanded partnerships, and a growing digital compliance offering, supporting its global presence and market penetration in healthcare disinfection solutions.
Tristel plc (TSNLF) Q2 2026 Earnings Call Transcript